vatalanib has been researched along with Dermatitis, Allergic Contact in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Iijima, M; Nakanishi, T; Sueki, H; Watanabe, H; Yamamoto, A; Yasuhara, H | 1 |
1 other study(ies) available for vatalanib and Dermatitis, Allergic Contact
Article | Year |
---|---|
Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.
Topics: Animals; Antigens, CD; Cell Migration Inhibition; Dermatitis, Allergic Contact; Dermis; Ear, External; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescein-5-isothiocyanate; Langerhans Cells; Laser-Doppler Flowmetry; Lymph Nodes; Mice; Mice, Inbred BALB C; Oxazolone; Phthalazines; Protein Kinase Inhibitors; Pyridines; Skin; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2007 |